TISSUE THERAPIES
TISSUE THERAPIES operates in Diversified Metals & Mining.
TISSUE THERAPIES (1TT) - Total Assets
Latest total assets as of December 2023: €3.62 Million EUR
Based on the latest financial reports, TISSUE THERAPIES (1TT) holds total assets worth €3.62 Million EUR as of December 2023.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
TISSUE THERAPIES - Total Assets Trend (2015–2023)
This chart illustrates how TISSUE THERAPIES’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
TISSUE THERAPIES - Asset Composition Analysis
Current Asset Composition (December 2023)
TISSUE THERAPIES's total assets of €3.62 Million consist of 87.5% current assets and 12.5% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 86.5% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €3.20K | 0.1% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2015–2023)
This chart illustrates how TISSUE THERAPIES's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: TISSUE THERAPIES's current assets represent 87.5% of total assets in 2023, a decrease from 91.9% in 2015.
- Cash Position: Cash and equivalents constituted 86.5% of total assets in 2023, down from 87.4% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 3.0% in 2015.
- Asset Diversification: The largest asset category is intangible assets at 0.1% of total assets.
TISSUE THERAPIES Competitors by Total Assets
Key competitors of TISSUE THERAPIES based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
XIWANG SPECIAL STEE (2XI.SG)
STU:2XI
|
Germany | €15.07 Billion |
|
LINDT & SPRUENGLI N - Dusseldorf Stock Exchang
DU:LSPN
|
Germany | €7.86 Billion |
|
PRICELINE.COM
BE:PCE1
|
Germany | €27.98 Billion |
|
PRICELINE GROUP (PCE1.SG)
STU:PCE1
|
Germany | €27.98 Billion |
|
MURPHY USA
BE:1MU
|
Germany | €4.40 Billion |
|
RESMED (RME.SG)
STU:RME
|
Germany | €7.22 Billion |
|
DIOS EXPLORATIONS
BE:BFM
|
Germany | €7.25 Million |
|
CHINA YUCHAI INTL (CYD.SG)
STU:CYD
|
Germany | €25.76 Billion |
TISSUE THERAPIES - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - TISSUE THERAPIES generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - TISSUE THERAPIES is currently not profitable relative to its asset base.
TISSUE THERAPIES - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 16.54 | 95.17 | 12.78 |
| Quick Ratio | 16.54 | 95.17 | 12.78 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €2.97 Million | € 5.35 Million | € 2.89 Million |
TISSUE THERAPIES - Advanced Valuation Insights
This section examines the relationship between TISSUE THERAPIES's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -38.5% |
| Total Assets | €3.62 Million |
| Market Capitalization | $200.17 USD |
Valuation Analysis
Below Book Valuation: The market values TISSUE THERAPIES's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: TISSUE THERAPIES's assets decreased by 38.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for TISSUE THERAPIES (2015–2023)
The table below shows the annual total assets of TISSUE THERAPIES from 2015 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | €3.62 Million | -38.47% |
| 2022-12-31 | €5.88 Million | -14.63% |
| 2021-12-31 | €6.89 Million | +111.50% |
| 2020-12-31 | €3.26 Million | +3.93% |
| 2019-12-31 | €3.13 Million | +12.82% |
| 2018-12-31 | €2.78 Million | -83.11% |
| 2015-12-31 | €16.45 Million | -- |